351437-78-0

Basic information

• Product Name: N-(4-Aminophenyl)cyclohexanecarboxamide
• Synonyms: N-(4-Aminophenyl)cyclohexanecarboxamide;AKOS BBV-009509;OTAVA-BB 1166816
• CAS NO: 351437-78-0
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 218.298
• Mol File: 351437-78-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-Aminophenyl)cyclohexanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Aminophenyl)cyclohexanecarboxamide(351437-78-0)
• EPA Substance Registry System: N-(4-Aminophenyl)cyclohexanecarboxamide(351437-78-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 351437-78-0(Hazardous Substances Data)

Upstream product

• 2719-27-9 cyclohexanylcarbonyl chloride 
• 305849-40-5 N-(4-nitrophenyl)cyclohexanecarboxamide 
• 100-01-6 4-nitro-aniline 

Relevant articles and documents

Tozasertib Analogues as Inhibitors of Necroptotic Cell Death

Receptor interacting protein kinase 1 (RIPK1) plays a crucial role in tumor necrosis factor (TNF)-induced necroptosis, suggesting that this pathway might be druggable. Most inhibitors of RIPK1 are classified as either type II or type III kinase inhibitors. This opened up some interesting perspectives for the discovery of novel inhibitors that target the active site of RIPK1. Tozasertib, a type I pan-aurora kinase (AurK) inhibitor, was found to show a very high affinity for RIPK1. Because tozasertib presents the typical structural elements of a type I kinase inhibitor, the development of structural analogues of tozasertib is a good starting point for identifying novel type I RIPK1 inhibitors. In this paper, we identified interesting inhibitors of mTNF-induced necroptosis with no significant effect on AurK A and B, resulting in no nuclear abnormalities as is the case for tozasertib. Compounds 71 and 72 outperformed tozasertib in an in vivo TNF-induced systemic inflammatory response syndrome (SIRS) mouse model.

NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS

Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative di

A new class of low-molecular-weight amphiphilic gelators

A new powerful class of low-molecular-weight amphiphilic compounds has been synthesized and their structure-property relationships with respect to their gelation ability of organic solvents have been investigated. These compounds are able to gel organic solvents over a broad range of polarity. Especially polar solvents such as valeronitrile and γ-butyrolactone can be gelled even at concentrations far below 1 wt %. It was found that the gelation ability of these asymmetrically substituted p-phenylendiamines depends on a well-balanced relation of the terminal head group, the units involved in hydrogen bonding (amide or urea groups), and on the length of the alkyl chain. With this class of new gelators it is possible to tailor thermal and mechanical properties in different organic solvents and open various application possibilities.